18 completed, 9 terminated, 4 unknown, 3 withdrawn. 21 Phase 2, 11 Phase 1, 5 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 7, Terminated 7, Unknown 4, Withdrawn 2, Active not recruiting 1 |
| Phase 1 | 11 | Completed 11 |
| Phase 3 | 5 | Completed 2, Terminated 2, Withdrawn 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow sitravatinib: new trials by email Literature Review of sitravatinib trials Research Report on sitravatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma Sitravatinib, Tislelizumab, sitravatinib-matching placebo - Hepatocellular Carcinoma | Phase 3 | Withdrawn | BeiGene | 2023-06-30 | 2023-06-07 | |
| Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy Tislelizumab, Sitravatinib - Metastatic Cervical Cancer | Phase 2 | Withdrawn | Australia New Zealand Gynaecological Oncology Group | 2023-06-01 | 2023-06-29 | |
| Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma Sitravatinib, Tislelizumab, Docetaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Terminated | BeiGene | 96 | 2022-10-03 | 2025-06-13 |
| Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. Tislelizumab, Sitravatinib - Uveal Melanoma With Liver Metastases | Phase 2 | Completed | Grupo Español Multidisciplinar de Melanoma | 16 | 2022-09-23 | 2026-06-01 |
| Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System pembrolizumab, Sitravatinib - Recurrent Endometrial Cancer, Solid Tumors | Phase 2 | Withdrawn | Haider Mahdi | 2022-09-08 | 2023-02-27 | |
| A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection Tislelizumab + Sitravatinib - Hepatocellular Carcinoma | Phase 2 | Unknown | Anhui Provincial Hospital | 40 | 2022-07-25 | 2023-03-22 |
| Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer Nivolumab, Quality-of-Life Assessment, Questionnaire Administration - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 15 | 2022-05-03 | 2026-03-20 |
| A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC Tislelizumab, Sitravatinib - Lung Cancer, Small Cell | Phase 2 | Unknown | Zhejiang Cancer Hospital | 21 | 2022-03-17 | 2023-09-26 |
| Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC Sitravatinib, Pembrolizumab - Carcinoma, Non-Small-Cell Lung, Lung Diseases | Phase 2 | Terminated | Sarah Goldberg | 9 | 2022-02-10 | 2025-04-17 |
| PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor. Sitravatinib 50 mg, Sitravatinib 100 mg, Itraconazole - Healthy Adults | Phase 1 | Completed | Mirati Therapeutics Inc. | 36 | 2022-02-02 | 2024-05-08 |
| Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma sitravatinib, tislelizumab - Melanoma | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 37 | 2021-11-01 | 2021-11-04 |
| Sitravatinib in Metastatic Breast Cancer Sitravatinib - Breast Cancer Stage IV, Triple Negative Breast Cancer | Phase 2 | Terminated | Xiang Zhang | 3 | 2021-09-22 | 2024-08-26 |
| Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Tislelizumab, Docetaxel, Sitravatinib - Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Terminated | BeiGene | 377 | 2021-07-27 | 2025-06-29 |
| A Study to Explore the Effect of Acid-reducing Agents Sitravatinib, Pantoprazole, Famotidine - Healthy Adults | Phase 1 | Completed | Mirati Therapeutics Inc. | 15 | 2021-07-07 | 2022-08-26 |
| Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study Sitravatinib, Nivolumab, Pembrolizumab - Advanced or Metastatic Solid Malignancies | Phase 2 / Phase 3 | Completed | Mirati Therapeutics Inc. | 49 | 2021-06-29 | 2026-08-04 |
| PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates Sitravatinib, Warfarin, Dextromethorphan - Advanced Solid Tumor | Phase 1 | Completed | Mirati Therapeutics Inc. | 40 | 2021-04-08 | 2024-05-08 |
| A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) Sitravatinib, Tislelizumab, Nab-paclitaxel - Metastatic Breast Cancer | Phase 2 | Active not recruiting | Fudan University | 98 | 2021-04-01 | 2026-09-21 |
| A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib sitravatinib - Healthy Adults | Phase 1 | Completed | Mirati Therapeutics Inc. | 36 | 2021-03-15 | 2022-04-06 |
| A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib sitravatinib - Hepatic Impairment | Phase 1 | Completed | Mirati Therapeutics Inc. | 30 | 2021-03-12 | 2023-10-23 |
| Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC Tislelizumab, Sitravatinib - Non-small Cell Lung Cancer | Phase 2 | Terminated | Fudan University | 5 | 2021-01-10 | 2024-01-29 |
Showing 20 of 35. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (6) · Carcinoma, Renal Cell (5) · Carcinoma, Hepatocellular (3) · Breast Neoplasms (2) · Lung Neoplasms (2) · Melanoma (2) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Clear-cell metastatic renal cell carcinoma (1) · Endometrial Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Head and Neck Neoplasms (1)
Mirati Therapeutics Inc. (12) · BeiGene (6) · Fudan University (2) · M.D. Anderson Cancer Center (2) · Anhui Provincial Hospital (1) · Australia New Zealand Gynaecological Oncology Group (1) · BeOne Medicines (1) · Columbia University (1) · Grupo Español Multidisciplinar de Melanoma (1) · Haider Mahdi (1) · Peking University Cancer Hospital & Institute (1) · Sarah Goldberg (1) · Seoul National University Hospital (1) · University Health Network, Toronto (1) · University of Birmingham (1)
United States (18) · China (10) · Australia (4) · South Korea (3) · Canada (2) · France (2) · Italy (2) · Spain (2) · United Kingdom (2) · Belgium (1) · Germany (1) · Hungary (1) · Israel (1) · Japan (1) · Malaysia (1)
Curtis Chin, MD (5) · Benjamin Izar, MD (1) · C. Kent Osborne, MD (1) · Do-Youn Oh, M.D., PhD. (1) · Gary W Middleton (1) · Haider Mahdi, MD (1) · Hirak Der-Torossian, MD (1) · Jeff Goh, MBBS, FRACP (1) · Josep Maria Piulats, M.D. Ph.D. (1) · Lillian Siu, MD (1) · Pavlos Msaoel (1) · Pavlos Msaouel (1)
PMID 32669708, PMID 34599023, PMID 35767205, PMID 38197138, PMID 39168901, PMID 39198847, PMID 39513224, PMID 39794332, PMID 40069402, PMID 40212021, PMID 41297674, PMID 41737914
2014 (1), 2019 (1), 2023 (1)